nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—Myelodysplastic syndrome—Temozolomide—malignant glioma	0.0358	0.0597	CcSEcCtD
Fludarabine—Pulmonary toxicity—Carmustine—malignant glioma	0.0328	0.0546	CcSEcCtD
Fludarabine—Fibrosis—Carmustine—malignant glioma	0.026	0.0434	CcSEcCtD
Fludarabine—SLC28A3—Transport of vitamins, nucleosides, and related molecules—APOD—malignant glioma	0.0183	0.0828	CbGpPWpGaD
Fludarabine—Opportunistic infection—Temozolomide—malignant glioma	0.0179	0.0298	CcSEcCtD
Fludarabine—Pulmonary fibrosis—Carmustine—malignant glioma	0.0169	0.0282	CcSEcCtD
Fludarabine—Pulmonary fibrosis—Temozolomide—malignant glioma	0.0163	0.0273	CcSEcCtD
Fludarabine—Myelosuppression—Carmustine—malignant glioma	0.0159	0.0265	CcSEcCtD
Fludarabine—Lung infiltration—Carmustine—malignant glioma	0.0159	0.0265	CcSEcCtD
Fludarabine—Myelosuppression—Temozolomide—malignant glioma	0.0153	0.0256	CcSEcCtD
Fludarabine—Transient ischaemic attack—Temozolomide—malignant glioma	0.0142	0.0238	CcSEcCtD
Fludarabine—SLC29A1—Transport of vitamins, nucleosides, and related molecules—APOD—malignant glioma	0.0136	0.0617	CbGpPWpGaD
Fludarabine—POLA1—retina—malignant glioma	0.0125	0.085	CbGeAlD
Fludarabine—Deep vein thrombosis—Temozolomide—malignant glioma	0.0118	0.0197	CcSEcCtD
Fludarabine—Adenosine monophosphate—PIM1—malignant glioma	0.0116	0.352	CrCbGaD
Fludarabine—Digestion impaired—Temozolomide—malignant glioma	0.0108	0.0179	CcSEcCtD
Fludarabine—RRM1—retina—malignant glioma	0.00989	0.0675	CbGeAlD
Fludarabine—Herpes zoster—Temozolomide—malignant glioma	0.00955	0.0159	CcSEcCtD
Fludarabine—Flavin adenine dinucleotide—POR—malignant glioma	0.0092	0.279	CrCbGaD
Fludarabine—RRM1—telencephalon—malignant glioma	0.0091	0.0621	CbGeAlD
Fludarabine—DCK—embryo—malignant glioma	0.00869	0.0593	CbGeAlD
Fludarabine—Adenosine triphosphate—ACVR1—malignant glioma	0.00855	0.26	CrCbGaD
Fludarabine—DCK—retina—malignant glioma	0.00768	0.0524	CbGeAlD
Fludarabine—Hearing impaired—Temozolomide—malignant glioma	0.00755	0.0126	CcSEcCtD
Fludarabine—SLC29A1—telencephalon—malignant glioma	0.0074	0.0505	CbGeAlD
Fludarabine—Respiratory failure—Temozolomide—malignant glioma	0.00732	0.0122	CcSEcCtD
Fludarabine—RRM1—medulla oblongata—malignant glioma	0.00715	0.0488	CbGeAlD
Fludarabine—DCK—telencephalon—malignant glioma	0.00707	0.0482	CbGeAlD
Fludarabine—Coma—Carmustine—malignant glioma	0.0068	0.0113	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—STMN1—malignant glioma	0.00671	0.0304	CbGpPWpGaD
Fludarabine—RRM1—midbrain—malignant glioma	0.00653	0.0446	CbGeAlD
Fludarabine—RRM1—spinal cord—malignant glioma	0.00637	0.0435	CbGeAlD
Fludarabine—POLA1—cerebellum—malignant glioma	0.00637	0.0434	CbGeAlD
Fludarabine—Phlebitis—Carmustine—malignant glioma	0.00627	0.0105	CcSEcCtD
Fludarabine—Deafness—Temozolomide—malignant glioma	0.00584	0.00973	CcSEcCtD
Fludarabine—Hepatic failure—Temozolomide—malignant glioma	0.00581	0.00968	CcSEcCtD
Fludarabine—DCK—medulla oblongata—malignant glioma	0.00555	0.0379	CbGeAlD
Fludarabine—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.0054	0.009	CcSEcCtD
Fludarabine—POLA1—brain—malignant glioma	0.00517	0.0353	CbGeAlD
Fludarabine—RRM1—central nervous system—malignant glioma	0.00517	0.0353	CbGeAlD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—STMN1—malignant glioma	0.00516	0.0234	CbGpPWpGaD
Fludarabine—DCK—midbrain—malignant glioma	0.00507	0.0346	CbGeAlD
Fludarabine—RRM1—cerebellum—malignant glioma	0.00505	0.0345	CbGeAlD
Fludarabine—Liver function test abnormal—Carmustine—malignant glioma	0.00499	0.00831	CcSEcCtD
Fludarabine—DCK—spinal cord—malignant glioma	0.00495	0.0338	CbGeAlD
Fludarabine—Dehydration—Temozolomide—malignant glioma	0.00485	0.00809	CcSEcCtD
Fludarabine—DCK—Purine metabolism—CAT—malignant glioma	0.00472	0.0214	CbGpPWpGaD
Fludarabine—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.0047	0.00784	CcSEcCtD
Fludarabine—Dysphagia—Carmustine—malignant glioma	0.00467	0.00778	CcSEcCtD
Fludarabine—Dysphagia—Temozolomide—malignant glioma	0.00451	0.00752	CcSEcCtD
Fludarabine—Pancytopenia—Carmustine—malignant glioma	0.00443	0.00739	CcSEcCtD
Fludarabine—Sweating increased—Temozolomide—malignant glioma	0.00439	0.00733	CcSEcCtD
Fludarabine—Neutropenia—Carmustine—malignant glioma	0.00437	0.00728	CcSEcCtD
Fludarabine—Bronchitis—Temozolomide—malignant glioma	0.00434	0.00723	CcSEcCtD
Fludarabine—Pancytopenia—Temozolomide—malignant glioma	0.00428	0.00714	CcSEcCtD
Fludarabine—Dysuria—Temozolomide—malignant glioma	0.00422	0.00703	CcSEcCtD
Fludarabine—Neutropenia—Temozolomide—malignant glioma	0.00422	0.00703	CcSEcCtD
Fludarabine—Hyperglycaemia—Carmustine—malignant glioma	0.00421	0.00702	CcSEcCtD
Fludarabine—SLC29A1—central nervous system—malignant glioma	0.0042	0.0287	CbGeAlD
Fludarabine—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00419	0.00699	CcSEcCtD
Fludarabine—Pneumonia—Carmustine—malignant glioma	0.00419	0.00698	CcSEcCtD
Fludarabine—SLC29A1—cerebellum—malignant glioma	0.00411	0.028	CbGeAlD
Fludarabine—RRM1—brain—malignant glioma	0.00411	0.028	CbGeAlD
Fludarabine—Renal failure—Carmustine—malignant glioma	0.00409	0.00682	CcSEcCtD
Fludarabine—Neuropathy peripheral—Carmustine—malignant glioma	0.00408	0.0068	CcSEcCtD
Fludarabine—Hyperglycaemia—Temozolomide—malignant glioma	0.00407	0.00678	CcSEcCtD
Fludarabine—Stomatitis—Carmustine—malignant glioma	0.00406	0.00676	CcSEcCtD
Fludarabine—Urinary tract infection—Carmustine—malignant glioma	0.00405	0.00674	CcSEcCtD
Fludarabine—Pneumonia—Temozolomide—malignant glioma	0.00405	0.00674	CcSEcCtD
Fludarabine—DCK—central nervous system—malignant glioma	0.00402	0.0274	CbGeAlD
Fludarabine—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00399	0.00665	CcSEcCtD
Fludarabine—Neuropathy peripheral—Temozolomide—malignant glioma	0.00394	0.00657	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TOP2A—malignant glioma	0.00393	0.0178	CbGpPWpGaD
Fludarabine—DCK—cerebellum—malignant glioma	0.00393	0.0268	CbGeAlD
Fludarabine—Stomatitis—Temozolomide—malignant glioma	0.00392	0.00654	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—APOD—malignant glioma	0.00392	0.0178	CbGpPWpGaD
Fludarabine—Urinary tract infection—Temozolomide—malignant glioma	0.00391	0.00652	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—STMN1—malignant glioma	0.00378	0.0171	CbGpPWpGaD
Fludarabine—Sinusitis—Temozolomide—malignant glioma	0.00377	0.00629	CcSEcCtD
Fludarabine—Haemoglobin—Carmustine—malignant glioma	0.00376	0.00626	CcSEcCtD
Fludarabine—Haemorrhage—Carmustine—malignant glioma	0.00374	0.00623	CcSEcCtD
Fludarabine—Hypoaesthesia—Carmustine—malignant glioma	0.00372	0.0062	CcSEcCtD
Fludarabine—Haemoglobin—Temozolomide—malignant glioma	0.00363	0.00605	CcSEcCtD
Fludarabine—Haemorrhage—Temozolomide—malignant glioma	0.00361	0.00602	CcSEcCtD
Fludarabine—Adenosine triphosphate—AKT1—malignant glioma	0.00361	0.109	CrCbGaD
Fludarabine—Visual impairment—Carmustine—malignant glioma	0.0036	0.006	CcSEcCtD
Fludarabine—Hypoaesthesia—Temozolomide—malignant glioma	0.00359	0.00599	CcSEcCtD
Fludarabine—Pharyngitis—Temozolomide—malignant glioma	0.00358	0.00597	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—STMN1—malignant glioma	0.00357	0.0162	CbGpPWpGaD
Fludarabine—Visual impairment—Temozolomide—malignant glioma	0.00348	0.0058	CcSEcCtD
Fludarabine—Erythema multiforme—Temozolomide—malignant glioma	0.00341	0.00569	CcSEcCtD
Fludarabine—Arrhythmia—Carmustine—malignant glioma	0.00334	0.00556	CcSEcCtD
Fludarabine—SLC29A1—brain—malignant glioma	0.00334	0.0228	CbGeAlD
Fludarabine—Alopecia—Carmustine—malignant glioma	0.0033	0.0055	CcSEcCtD
Fludarabine—Malnutrition—Carmustine—malignant glioma	0.00325	0.00542	CcSEcCtD
Fludarabine—Chills—Temozolomide—malignant glioma	0.00324	0.0054	CcSEcCtD
Fludarabine—Alopecia—Temozolomide—malignant glioma	0.00319	0.00532	CcSEcCtD
Fludarabine—POLA1—Extension of Telomeres—TERT—malignant glioma	0.00319	0.0145	CbGpPWpGaD
Fludarabine—DCK—brain—malignant glioma	0.00319	0.0218	CbGeAlD
Fludarabine—Malnutrition—Temozolomide—malignant glioma	0.00314	0.00524	CcSEcCtD
Fludarabine—RRM1—Nucleotide metabolism—CAT—malignant glioma	0.00308	0.014	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TOP2A—malignant glioma	0.00302	0.0137	CbGpPWpGaD
Fludarabine—Anaemia—Carmustine—malignant glioma	0.00301	0.00501	CcSEcCtD
Fludarabine—Agitation—Carmustine—malignant glioma	0.00299	0.00498	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—APOD—malignant glioma	0.00292	0.0133	CbGpPWpGaD
Fludarabine—Ill-defined disorder—Temozolomide—malignant glioma	0.00292	0.00486	CcSEcCtD
Fludarabine—Leukopenia—Carmustine—malignant glioma	0.00291	0.00485	CcSEcCtD
Fludarabine—Anaemia—Temozolomide—malignant glioma	0.00291	0.00484	CcSEcCtD
Fludarabine—Agitation—Temozolomide—malignant glioma	0.00289	0.00482	CcSEcCtD
Fludarabine—Malaise—Temozolomide—malignant glioma	0.00283	0.00473	CcSEcCtD
Fludarabine—Convulsion—Carmustine—malignant glioma	0.00282	0.0047	CcSEcCtD
Fludarabine—Leukopenia—Temozolomide—malignant glioma	0.00281	0.00469	CcSEcCtD
Fludarabine—Myalgia—Carmustine—malignant glioma	0.00277	0.00462	CcSEcCtD
Fludarabine—Cough—Temozolomide—malignant glioma	0.00274	0.00457	CcSEcCtD
Fludarabine—Convulsion—Temozolomide—malignant glioma	0.00272	0.00454	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	0.00271	0.0123	CbGpPWpGaD
Fludarabine—Confusional state—Carmustine—malignant glioma	0.00268	0.00446	CcSEcCtD
Fludarabine—Myalgia—Temozolomide—malignant glioma	0.00268	0.00446	CcSEcCtD
Fludarabine—Arthralgia—Temozolomide—malignant glioma	0.00268	0.00446	CcSEcCtD
Fludarabine—Oedema—Carmustine—malignant glioma	0.00265	0.00443	CcSEcCtD
Fludarabine—Discomfort—Temozolomide—malignant glioma	0.00264	0.00441	CcSEcCtD
Fludarabine—Infection—Carmustine—malignant glioma	0.00264	0.0044	CcSEcCtD
Fludarabine—Thrombocytopenia—Carmustine—malignant glioma	0.0026	0.00433	CcSEcCtD
Fludarabine—Confusional state—Temozolomide—malignant glioma	0.00259	0.00431	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	0.00257	0.0116	CbGpPWpGaD
Fludarabine—Anaphylactic shock—Temozolomide—malignant glioma	0.00257	0.00428	CcSEcCtD
Fludarabine—Oedema—Temozolomide—malignant glioma	0.00257	0.00428	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—COX8A—malignant glioma	0.00256	0.0116	CbGpPWpGaD
Fludarabine—Infection—Temozolomide—malignant glioma	0.00255	0.00425	CcSEcCtD
Fludarabine—Anorexia—Carmustine—malignant glioma	0.00253	0.00422	CcSEcCtD
Fludarabine—Nervous system disorder—Temozolomide—malignant glioma	0.00252	0.00419	CcSEcCtD
Fludarabine—Thrombocytopenia—Temozolomide—malignant glioma	0.00251	0.00419	CcSEcCtD
Fludarabine—Hyperhidrosis—Temozolomide—malignant glioma	0.00248	0.00413	CcSEcCtD
Fludarabine—Anorexia—Temozolomide—malignant glioma	0.00245	0.00408	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00242	0.00403	CcSEcCtD
Fludarabine—Paraesthesia—Carmustine—malignant glioma	0.00238	0.00397	CcSEcCtD
Fludarabine—DCK—Nucleotide metabolism—CAT—malignant glioma	0.00237	0.0108	CbGpPWpGaD
Fludarabine—Dyspnoea—Carmustine—malignant glioma	0.00237	0.00395	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—FTH1—malignant glioma	0.00234	0.0106	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00234	0.0039	CcSEcCtD
Fludarabine—Decreased appetite—Carmustine—malignant glioma	0.00231	0.00385	CcSEcCtD
Fludarabine—Paraesthesia—Temozolomide—malignant glioma	0.0023	0.00384	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Carmustine—malignant glioma	0.00229	0.00382	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	0.00229	0.0104	CbGpPWpGaD
Fludarabine—Dyspnoea—Temozolomide—malignant glioma	0.00229	0.00381	CcSEcCtD
Fludarabine—Constipation—Carmustine—malignant glioma	0.00227	0.00378	CcSEcCtD
Fludarabine—Pain—Carmustine—malignant glioma	0.00227	0.00378	CcSEcCtD
Fludarabine—Dyspepsia—Temozolomide—malignant glioma	0.00226	0.00376	CcSEcCtD
Fludarabine—Decreased appetite—Temozolomide—malignant glioma	0.00223	0.00372	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00221	0.00369	CcSEcCtD
Fludarabine—Fatigue—Temozolomide—malignant glioma	0.00221	0.00369	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TOP2A—malignant glioma	0.00221	0.01	CbGpPWpGaD
Fludarabine—Pain—Temozolomide—malignant glioma	0.00219	0.00366	CcSEcCtD
Fludarabine—Constipation—Temozolomide—malignant glioma	0.00219	0.00366	CcSEcCtD
Fludarabine—Feeling abnormal—Carmustine—malignant glioma	0.00219	0.00365	CcSEcCtD
Fludarabine—Feeling abnormal—Temozolomide—malignant glioma	0.00211	0.00352	CcSEcCtD
Fludarabine—Body temperature increased—Carmustine—malignant glioma	0.0021	0.0035	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	0.00209	0.00949	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP1B2—malignant glioma	0.00205	0.00928	CbGpPWpGaD
Fludarabine—Body temperature increased—Temozolomide—malignant glioma	0.00203	0.00338	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—STMN1—malignant glioma	0.00201	0.00913	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—APOD—malignant glioma	0.00199	0.00903	CbGpPWpGaD
Fludarabine—Hypersensitivity—Carmustine—malignant glioma	0.00196	0.00326	CcSEcCtD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—malignant glioma	0.00195	0.00882	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—COX8A—malignant glioma	0.00191	0.00866	CbGpPWpGaD
Fludarabine—Asthenia—Carmustine—malignant glioma	0.0019	0.00318	CcSEcCtD
Fludarabine—Hypersensitivity—Temozolomide—malignant glioma	0.00189	0.00315	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—CDKN2A—malignant glioma	0.00185	0.0084	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	0.00184	0.00835	CbGpPWpGaD
Fludarabine—Asthenia—Temozolomide—malignant glioma	0.00184	0.00307	CcSEcCtD
Fludarabine—Diarrhoea—Carmustine—malignant glioma	0.00182	0.00303	CcSEcCtD
Fludarabine—Pruritus—Temozolomide—malignant glioma	0.00182	0.00303	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—malignant glioma	0.00178	0.00807	CbGpPWpGaD
Fludarabine—Diarrhoea—Temozolomide—malignant glioma	0.00176	0.00293	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC6A3—malignant glioma	0.00175	0.00795	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—FTH1—malignant glioma	0.00175	0.00792	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—RTEL1—malignant glioma	0.0017	0.00772	CbGpPWpGaD
Fludarabine—Vomiting—Carmustine—malignant glioma	0.00169	0.00281	CcSEcCtD
Fludarabine—Rash—Carmustine—malignant glioma	0.00167	0.00279	CcSEcCtD
Fludarabine—Dermatitis—Carmustine—malignant glioma	0.00167	0.00279	CcSEcCtD
Fludarabine—Headache—Carmustine—malignant glioma	0.00166	0.00277	CcSEcCtD
Fludarabine—Vomiting—Temozolomide—malignant glioma	0.00163	0.00272	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	0.00163	0.00738	CbGpPWpGaD
Fludarabine—Rash—Temozolomide—malignant glioma	0.00162	0.0027	CcSEcCtD
Fludarabine—Dermatitis—Temozolomide—malignant glioma	0.00162	0.00269	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—TUBG2—malignant glioma	0.00161	0.00729	CbGpPWpGaD
Fludarabine—Headache—Temozolomide—malignant glioma	0.00161	0.00268	CcSEcCtD
Fludarabine—Nausea—Carmustine—malignant glioma	0.00158	0.00263	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—MDM2—malignant glioma	0.00156	0.00708	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—TOP2A—malignant glioma	0.00156	0.00706	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—RAF1—malignant glioma	0.00156	0.00705	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP1B2—malignant glioma	0.00153	0.00692	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	0.00153	0.00692	CbGpPWpGaD
Fludarabine—Nausea—Temozolomide—malignant glioma	0.00152	0.00254	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	0.00151	0.00686	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	0.0015	0.0068	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—APOD—malignant glioma	0.00148	0.00673	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	0.00145	0.00656	CbGpPWpGaD
Fludarabine—POLA1—Telomere Maintenance—TERT—malignant glioma	0.00145	0.00656	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TUBG2—malignant glioma	0.00144	0.00652	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	0.00137	0.00623	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	0.00136	0.00618	CbGpPWpGaD
Fludarabine—DCK—Metabolism—RTEL1—malignant glioma	0.00131	0.00594	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC6A3—malignant glioma	0.00131	0.00593	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	0.00129	0.00585	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—MYC—malignant glioma	0.00125	0.00569	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	0.00122	0.00552	CbGpPWpGaD
Fludarabine—POLA1—Chromosome Maintenance—TERT—malignant glioma	0.0012	0.00546	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—MDM2—malignant glioma	0.0012	0.00545	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—RAF1—malignant glioma	0.0012	0.00543	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	0.00118	0.00535	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN2B—malignant glioma	0.00112	0.00506	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	0.00109	0.00495	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—MYC—malignant glioma	0.00109	0.00495	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	0.00106	0.00479	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	0.00104	0.00474	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CDKN2A—malignant glioma	0.00104	0.00473	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—TFRC—malignant glioma	0.00102	0.00462	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PLK1—malignant glioma	0.000988	0.00448	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—HIST1H3B—malignant glioma	0.000978	0.00444	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—COX8A—malignant glioma	0.000978	0.00443	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000936	0.00425	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	0.000917	0.00416	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—malignant glioma	0.000896	0.00406	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000891	0.00404	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	0.000889	0.00403	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—malignant glioma	0.000879	0.00399	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—RAF1—malignant glioma	0.000876	0.00397	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	0.000852	0.00387	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	0.000845	0.00383	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	0.000844	0.00383	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—malignant glioma	0.000839	0.00381	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	0.000832	0.00377	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ASMT—malignant glioma	0.000831	0.00377	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	0.000829	0.00376	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	0.00082	0.00372	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	0.000802	0.00364	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—BCAN—malignant glioma	0.000782	0.00354	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	0.000768	0.00348	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—TFRC—malignant glioma	0.00076	0.00345	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—H3F3A—malignant glioma	0.000756	0.00343	CbGpPWpGaD
Fludarabine—DCK—Metabolism—COX8A—malignant glioma	0.000752	0.00341	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	0.000745	0.00338	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PLK1—malignant glioma	0.000739	0.00335	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—HIST1H3B—malignant glioma	0.000732	0.00332	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—MYC—malignant glioma	0.000707	0.00321	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	0.0007	0.00317	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000698	0.00317	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—malignant glioma	0.000689	0.00313	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	0.000686	0.00311	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000664	0.00301	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PLK1—malignant glioma	0.00066	0.00299	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—HIST1H3B—malignant glioma	0.000654	0.00297	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ASMT—malignant glioma	0.00064	0.0029	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—malignant glioma	0.000638	0.00289	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	0.000632	0.00287	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—IDH2—malignant glioma	0.00063	0.00286	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	0.000614	0.00279	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—malignant glioma	0.000614	0.00279	CbGpPWpGaD
Fludarabine—DCK—Metabolism—BCAN—malignant glioma	0.000602	0.00273	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	0.000595	0.0027	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP2B6—malignant glioma	0.000592	0.00269	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	0.000588	0.00267	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	0.000581	0.00264	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—TOP2A—malignant glioma	0.000571	0.00259	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	0.000569	0.00258	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—H3F3A—malignant glioma	0.000565	0.00256	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—YWHAE—malignant glioma	0.000545	0.00247	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—IDH1—malignant glioma	0.000542	0.00246	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	0.000542	0.00246	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	0.000537	0.00244	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—SPHK1—malignant glioma	0.000524	0.00238	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP2C18—malignant glioma	0.000514	0.00233	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—MYC—malignant glioma	0.000513	0.00233	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TOP2A—malignant glioma	0.00051	0.00231	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—H3F3A—malignant glioma	0.000505	0.00229	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—malignant glioma	0.000504	0.00229	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	0.000501	0.00227	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	0.000494	0.00224	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—YWHAE—malignant glioma	0.000487	0.00221	CbGpPWpGaD
Fludarabine—DCK—Metabolism—IDH2—malignant glioma	0.000485	0.0022	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	0.000477	0.00216	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	0.000476	0.00216	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—BIRC5—malignant glioma	0.000472	0.00214	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	0.000469	0.00213	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	0.000467	0.00212	CbGpPWpGaD
Fludarabine—POLA1—S Phase—MYC—malignant glioma	0.000466	0.00211	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	0.000462	0.0021	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP2B6—malignant glioma	0.000456	0.00207	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	0.000452	0.00205	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—MYC—malignant glioma	0.000432	0.00196	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	0.000419	0.0019	CbGpPWpGaD
Fludarabine—DCK—Metabolism—IDH1—malignant glioma	0.000417	0.00189	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTT1—malignant glioma	0.000415	0.00188	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN2B—malignant glioma	0.000409	0.00185	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—RAF1—malignant glioma	0.000404	0.00183	CbGpPWpGaD
Fludarabine—DCK—Metabolism—SPHK1—malignant glioma	0.000403	0.00183	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	0.000403	0.00183	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP2C18—malignant glioma	0.000395	0.00179	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	0.000394	0.00179	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS1—malignant glioma	0.000389	0.00177	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—BRCA2—malignant glioma	0.000369	0.00167	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN2B—malignant glioma	0.000366	0.00166	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—BCHE—malignant glioma	0.000362	0.00164	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—SLC5A5—malignant glioma	0.000357	0.00162	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	0.000356	0.00161	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—BIRC5—malignant glioma	0.000353	0.0016	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	0.000327	0.00148	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	0.00032	0.00145	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTT1—malignant glioma	0.00032	0.00145	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—BIRC5—malignant glioma	0.000316	0.00143	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TERT—malignant glioma	0.000306	0.00139	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	0.000305	0.00138	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	0.000303	0.00137	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—RAF1—malignant glioma	0.000301	0.00137	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS1—malignant glioma	0.0003	0.00136	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTP1—malignant glioma	0.000288	0.00131	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CAT—malignant glioma	0.00028	0.00127	CbGpPWpGaD
Fludarabine—DCK—Metabolism—BCHE—malignant glioma	0.000279	0.00126	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	0.000278	0.00126	CbGpPWpGaD
Fludarabine—DCK—Metabolism—SLC5A5—malignant glioma	0.000275	0.00125	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	0.000269	0.00122	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—NCOR1—malignant glioma	0.000265	0.0012	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—malignant glioma	0.000234	0.00106	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	0.000227	0.00103	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTP1—malignant glioma	0.000222	0.001	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CAV1—malignant glioma	0.000216	0.000978	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CAT—malignant glioma	0.000216	0.000978	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN2A—malignant glioma	0.000209	0.000948	CbGpPWpGaD
Fludarabine—DCK—Metabolism—NCOR1—malignant glioma	0.000204	0.000923	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MDM2—malignant glioma	0.000203	0.00092	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CG—malignant glioma	0.000196	0.000891	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PPARG—malignant glioma	0.00019	0.00086	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CD—malignant glioma	0.000173	0.000783	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CAV1—malignant glioma	0.000166	0.000753	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MYC—malignant glioma	0.000159	0.000719	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CG—malignant glioma	0.000151	0.000686	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CB—malignant glioma	0.000151	0.000683	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS2—malignant glioma	0.000149	0.000676	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPARG—malignant glioma	0.000146	0.000662	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MYC—malignant glioma	0.000142	0.000643	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CD—malignant glioma	0.000133	0.000603	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTEN—malignant glioma	0.00013	0.00059	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—malignant glioma	0.000116	0.000528	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CB—malignant glioma	0.000116	0.000525	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS2—malignant glioma	0.000115	0.000521	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTEN—malignant glioma	0.0001	0.000454	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CA—malignant glioma	9.18e-05	0.000416	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—AKT1—malignant glioma	7.5e-05	0.00034	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CA—malignant glioma	7.06e-05	0.00032	CbGpPWpGaD
Fludarabine—DCK—Metabolism—AKT1—malignant glioma	5.77e-05	0.000262	CbGpPWpGaD
